Welcome to our dedicated page for Cognition Therapeutics news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on Cognition Therapeutics stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company based in Pittsburgh, Pennsylvania. Established in 2007, the company is dedicated to discovering and developing small-molecule therapeutics aimed at treating age-related degenerative diseases and disorders of the central nervous system and retina.
At the heart of Cognition Therapeutics' innovation is its proprietary biology and chemistry platforms, which are utilized to identify novel drug targets and create disease-modifying therapies. The company's flagship product candidate, CT1812, is an orally administered small-molecule antagonist designed to breach the blood-brain barrier. CT1812 binds selectively to the S2R complex, potentially offering a unique therapeutic approach for patients.
Current Projects and Achievements:
- CT1812 is currently being evaluated in Phase 2 clinical trials for conditions such as Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD).
- Recent 2023 milestones include completing enrollment for the SHINE Study in mild-to-moderate Alzheimer's disease and initiating new clinical studies for early Alzheimer's and dry AMD.
- The SHIMMER study for mild-to-moderate DLB has also reached its target enrollment, with top-line results anticipated in the latter half of 2024.
The company has made significant strides in advancing its clinical programs. In 2023, the FDA approved the first disease-modifying biologics for Alzheimer’s disease, which has rejuvenated research and investment in this critical area. Cognition Therapeutics is leveraging this momentum in its ongoing research and clinical trials.
Financial Overview:
For the year ending December 31, 2023, Cognition Therapeutics reported cash and cash equivalents of approximately $29.9 million. Additional capital from a March 2024 offering has bolstered their financial position, providing the company with sufficient funds to support operations and capital expenditures through May 2025.
Research and development expenses for 2023 were $37.2 million, an increase from $30.3 million in 2022, reflecting higher costs associated with Phase 2 trials and personnel. General and administrative expenses remained relatively stable at $13.5 million.
The company continues to foster collaborations and partnerships to advance its scientific goals. Notably, the SHIMMER study is supported by a significant grant from the National Institute on Aging (NIA), totaling approximately $30 million.
For ongoing updates and detailed information about Cognition Therapeutics, visit their website at cogrx.com.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) will release its second-quarter financial results for the period ending June 30, 2022, on August 9, 2022, before market opening. The company focuses on developing small molecule therapeutics for age-related central nervous system and retinal disorders. Its lead candidate, CT1812, is in clinical trials for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. This announcement highlights the company's ongoing commitment to addressing serious health issues related to aging.
Cognition Therapeutics (NASDAQ: CGTX) announces its participation in the 2022 Alzheimer’s Association International Conference (AAIC) from July 31 to August 4. The company will present new proteomic analyses from the SPARC clinical study, showcasing the impact of CT1812 on Alzheimer’s disease biomarkers. CT1812, an oral small molecule targeting sigma-2 receptors, shows potential therapeutic benefits. Cognition is conducting multiple clinical studies, with results from SHINE and SEQUEL expected in early 2023. The company has secured over $168 million in grant funding.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has initiated its Phase 2 SHIMMER clinical trial for CT1812, targeting dementia with Lewy bodies (DLB). The trial, supported by a $30 million NIA grant, aims to enroll 120 adults aged 50-80 with DLB. CT1812 is an oral therapeutic intended to address DLB's underlying biology, which currently lacks disease-modifying treatments. Primary investigator Dr. James E. Galvin emphasized the trial's importance in exploring a unique mechanism of action against this severe condition.
Cognition Therapeutics (Nasdaq: CGTX) will present at the JMP Securities Life Sciences Conference on June 16, 2022. CEO Lisa Ricciardi will provide an update on the development of small-molecule therapeutics for age-related degenerative diseases. The presentation will focus on their lead candidate, CT1812, which is being studied in clinical programs targeting Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. A live and archived webcast will be available online.
Cognition Therapeutics (Nasdaq: CGTX) will host a virtual KOL symposium on June 9, 2022, from 10:00 - 11:30 a.m. ET, focusing on dry age-related macular degeneration (dry AMD). The company plans to initiate a Phase 2 study with its lead candidate, CT1812, in the second half of 2022. Notable speakers include Dr. Mary Hamby and Dr. Karl Csaky, who will discuss recent findings and the current treatment landscape for dry AMD. The event is free to register and will also offer a live Q&A session.
Cognition Therapeutics (Nasdaq: CGTX) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. CEO Lisa Ricciardi and VP of Research Mary Hamby will present on May 25 at 3:30 p.m. EDT. The event will be accessible via a live and archived webcast on both the conference platform and the company's investor website. Registered investors can also schedule one-on-one meetings with management during the conference, aimed at fostering investor relations.
Cognition Therapeutics (NASDAQ: CGTX) announced the commencement of patient dosing in the second cohort of its Phase 2 SHINE study focusing on mild-to-moderate Alzheimer’s disease. The company plans to enroll patients in a dry AMD trial and the START trial in collaboration with the Alzheimer’s Clinical Trials Consortium in the second half of 2022. Financially, the company's Q1 2022 net loss was $3.8 million, or $(0.17) per share, compared to a loss of $0.9 million, or $(1.64) per share, in Q1 2021. As of March 31, 2022, cash reserves stood at $51.5 million.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it will release its financial results for Q1 2022 on May 11, 2022. The company focuses on developing small molecule therapeutics for age-related degenerative diseases, specifically targeting Alzheimer's disease and related conditions with its lead candidate CT1812. Cognition aims to leverage its unique mechanism to regulate impaired pathways in these diseases. The announcement corrects the report date previously stated as May 10, 2022.
Cognition Therapeutics (NASDAQ: CGTX) announced it will report its financial results for Q1 2022 on May 11, 2022. The company focuses on therapies for age-related degenerative diseases in the central nervous system and retina, with its lead candidate CT1812 under investigation for conditions like Alzheimer’s and dry age-related macular degeneration. Cognition aims to innovate treatments by targeting σ-2 receptors, offering a distinct mechanism compared to current therapies.
Cognition Therapeutics (NASDAQ: CGTX) showcased a poster at the ARVO meeting, highlighting that sigma-2 receptor modulators can restore the normal functioning of retinal pigment epithelial (RPE) cells impaired by dry age-related macular degeneration (AMD).
CT1812, Cognition's lead candidate, demonstrated the ability to rescue vital functions of RPE cells in in vitro models. The company plans to initiate a Phase 2 clinical trial with CT1812 in patients with dry AMD in late 2022. Dry AMD affects around 190 million individuals globally, making it a significant health concern.
FAQ
What is the current stock price of Cognition Therapeutics (CGTX)?
What is the market cap of Cognition Therapeutics (CGTX)?
What does Cognition Therapeutics, Inc. specialize in?
What is CT1812?
What recent achievements has Cognition Therapeutics made?
How is Cognition Therapeutics funded?
What are the company's main areas of research?
Where is Cognition Therapeutics located?
What are the financial highlights for Cognition Therapeutics in 2023?
How does CT1812 work?
What are some key milestones expected in 2024?
How can I stay updated on Cognition Therapeutics’ progress?
